The FDAs decision was supported by the Phase III SUNLIGHT trial, where the LonsurfAvastin combination led to a median overall survival of 10.8 months versus 7.5 months on Lonsurf monotherapy, for a 39% reduction in risk of death
Future directions include: establishing formal reference ranges for plasma GSH
According to the DoDs Operation Supplement Safety (OPSS) program, BPC-157: Is not authorized for use by Service Members and is considered a prohibited substance. This classification places BPC-157 on the same level as SARMs and other unapproved substances that are banned for military personnel due to lack of safety, purity concerns, and performance-altering effects
White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, Lopez-Sendon J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L
Drug interaction considerations GLP-1 medications can affect gastric emptying and may alter the absorption of oral medications taken at the same time
Grapefruit and medication: A cautionary note
